|Videos|October 26, 2017

Adults Aged 65 and Older Need to Get Their Flu Shots: Here's Why

William Schaffner, MD, explains why adults aged 65 and older need to receive the flu shot.

William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, explains why adults aged 65 and older need to receive the flu shot.

Interview Transcript (modified slightly for readability):

"We vaccinate two-thirds of the people in the United States who are aged 65 and older each year, and that’s a terrific achievement, but think about it: that means one-third of the population, 15 million people who are 65 and older still do not avail themselves of vaccination. We have to do better as providers, and I hope we can motivate those individuals to come in and request influenza immunization.

You know, people aged 65 and older have a diminished immune system. It doesn’t work as well; it’s not as responsive as the immune system in younger people, and so, they are disproportionately made ill, they get more serious illness when they’re infected with influenza.

On top of that, people aged 65 and older begin to accumulate a number of chronic illnesses—heart disease, diabetes, lung disease, asthma—and that makes the impact of flu even more serious because all of those chronic illnesses predispose to pneumonia and other serious complications of influenza."


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.